…agents that undergo enterohepatic or enteroenteric recirculation, including carbamazepine, theophylline and quinine. Repeated dosing may also be appropriate after large ingestions of modified release preparations…

…G, 25 mm 90° 1–2 mL Deltoid, BMI 35 or a large arm 23 G, 38 mm 90° 1–2 mL Vastus lateralis, infant…

…cardiac specific but the cTnT assays also detect proteins released from skeletal muscle. Consequently, skeletal muscle damage or inflammation may result in elevated cTnT levels…

…necrosis and cardiac troponin release meeting the criteria of the universal definition of MI. Clinically, UA is defined by one or more of the following…

…a dialysis patient, in severe acute kidney injury, in treatment failure or in ongoing massive potassium release. In cardiac arrest with suspected hyperkalaemia, advanced life…

…when a modified release preparation is started in an opioid naive patient, or when a conversion between drugs is made without reduction for incomplete cross…

…estimated quantity the time, and whether the intake was single or repeated a modified release preparation or a combination product concurrent drugs, alcohol and illicit…

…troponin release that does not fulfil the criteria for ischaemic myocardial infarction. It may be acute, when serial troponin values show a dynamic change, or…

…is myocardial ischaemia caused by an acute coronary process. Myocardial injury leads to release of cardiac troponin, but troponin elevation is not specific for myocardial…

…through intimal thickening. DES release antiproliferative and anti inflammatory agents from the stent surface and have substantially reduced this process compared with BMS. Neoatherosclerosis Neoatherosclerosis…